JPMorgan Starts Halozyme Therapeutics (HALO) at Overweight
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $38.97 +0.67%
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
JPMorgan initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with an Overweight rating and a price target of $13.00.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $9.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Starts Auna SA (AUNA) at Buy, 'Just what the doctor prescribed'
- BofA Securities Reinstates Indraprastha Gas Ltd. (IGL:IN) at Buy
- Halozyme to Report First Quarter 2024 Financial and Operating Results
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
